Faropenem

Faropenem

Clinical data
Routes of administration	Oral
Identifiers
IUPAC name (5R,6R)-6-(1-hydroxyethyl)-7-oxo-3-[(2R)- oxolan-2-yl]-4-thia-1-azabicyclo[3.2.0] hept-2-ene-2-carboxylic acid
CAS Number	106560-14-9
PubChem CID	65894
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C12H15NO5S
Molar mass	285.317 g/mol

WikiDoc Resources for Faropenem
Articles
Most recent articles on Faropenem Most cited articles on Faropenem Review articles on Faropenem Articles on Faropenem in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Faropenem Images of Faropenem Photos of Faropenem Podcasts & MP3s on Faropenem Videos on Faropenem
Evidence Based Medicine
Cochrane Collaboration on Faropenem Bandolier on Faropenem TRIP on Faropenem
Clinical Trials
Ongoing Trials on Faropenem at Clinical Trials.gov Trial results on Faropenem Clinical Trials on Faropenem at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Faropenem NICE Guidance on Faropenem NHS PRODIGY Guidance FDA on Faropenem CDC on Faropenem
Books
Books on Faropenem
News
Faropenem in the news Be alerted to news on Faropenem News trends on Faropenem
Commentary
Blogs on Faropenem
Definitions
Definitions of Faropenem
Patient Resources / Community
Patient resources on Faropenem Discussion groups on Faropenem Patient Handouts on Faropenem Directions to Hospitals Treating Faropenem Risk calculators and risk factors for Faropenem
Healthcare Provider Resources
Symptoms of Faropenem Causes & Risk Factors for Faropenem Diagnostic studies for Faropenem Treatment of Faropenem
Continuing Medical Education (CME)
CME Programs on Faropenem
International
Faropenem en Espanol Faropenem en Francais
Business
Faropenem in the Marketplace Patents on Faropenem
Experimental / Informatics
List of terms related to Faropenem

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Faropenem is an orally-active beta-lactam antibiotic belonging to the penem group. It is the first orally-active penem antibiotic. Faropenem was developed by Daiichi Asubio Pharma, which markets it in two forms.

• The sodium salt faropenem sodium, available under the trade name Farom, has been marketed in Japan since 1997. (Template:PubChem)
• The prodrug form faropenem medoxomil (also known as faropenem daloxate) has been licensed from Daiichi Asubio Pharma by Replidyne, which plans to market it in conjunction with Forest Pharmaceuticals. The trade name proposed for the product was Orapem but company officials recently announced that this name was rejected by the FDA. (Q1 06 Investor Conf Call)(Template:PubChem)

The company also stated their hope to have the product available for commercial sale months before the 2007 influenza season.

Clinical use

Faropenem has yet to receive marketing approval in the United States, and was submitted for consideration by the United States Food and Drug Administration (FDA) on 20 December 2005. The new drug application (NDA) dossier submitted included four proposed indications:

• acute bacterial sinusitis
• community acquired pneumonia
• acute exacerbations of chronic bronchitis
• uncomplicated skin and skin structure infections

External links

• Replidyne website
• Daiichi Asubio Pharma products page